Cartesian Therapeutics, Inc. Cash and Restricted Cash
Cartesian Therapeutics, Inc. (RNAC) had Cash and Restricted Cash of $149.34 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $149.34M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $120.38M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $126.87M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $145.12M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $149.34M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $120.38M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $126.87M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $145.12M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $162.06M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $182.10M 10-Q · filed 2026-04-30 |
| 2024-12-31 | $214.28M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $220.87M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $88.90M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $104.80M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $78.29M 10-K · filed 2026-03-09 |
| 2023-09-30 | $80.98M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $115.00M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $127.53M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $108.04M 10-K · filed 2025-03-13 |
| 2022-09-30 | $114.44M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $139.44M 10-Q · filed 2023-08-17 |
| 2022-03-31 | $114.82M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $115.44M 10-K · filed 2024-03-07 |
| 2021-09-30 | $116.02M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $127.13M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $126.79M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $140.06M 10-K · filed 2024-03-07 |
| 2020-09-30 | $147.64M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $61.39M 10-Q · filed 2021-08-12 |
| 2020-03-31 | $74.26M 10-Q · filed 2021-05-13 |
| 2019-12-31 | $91.55M 10-K · filed 2023-03-02 |
| 2019-09-30 | $35.89M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $30.48M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $32.45M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $37.68M 10-K · filed 2022-03-10 |
| 2018-09-30 | $50.76M 10-Q · filed 2019-11-08 |
| 2018-06-30 | $60.57M 10-Q · filed 2019-08-08 |
| 2018-03-31 | $58.63M 10-Q · filed 2019-05-09 |
| 2017-12-31 | $71.03M 10-K · filed 2021-03-12 |
| 2017-09-30 | $72.54M 10-Q · filed 2018-11-08 |
| 2017-06-30 | $83.02M 10-Q · filed 2018-08-08 |
| 2017-03-31 | $27.03M 10-Q · filed 2018-05-09 |
| 2016-12-31 | $59.05M 10-K · filed 2020-03-12 |
| 2015-12-31 | $32.78M 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |